Syncromune: Funding, Investors & Team (Oct 2026)
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.
Syncromune has raised $100M across 1 funding round on record, the most recent a Series A of $100M announced in Dec 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Syncromune Company Profile and Key Stats
Latest funding round on record: Dec 2024.
Syncromune Funding Rounds
Syncromune Founders and Leadership Team
Contact details for the Syncromune team: 1 of 1 has an email address on file.
Start 14-day free trial →Syncromune Funding Compared to Other Biotechnology Startups
Syncromune's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Syncromune in Biotechnology and Fort Lauderdale
Companies Similar to Syncromune
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Syncromune Funding FAQs
What does Syncromune do?
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.
How much funding has Syncromune raised?
Syncromune has raised $100M across 1 round on record. The most recent is a Series A of $100M announced in Dec 2024.
When did Syncromune last raise funding?
Syncromune's most recent funding round on record is a Series A of $100M, announced in Dec 2024.
Who founded Syncromune?
FundedIQ lists Eamonn Hobbs (Founder) at Syncromune.
Where is Syncromune headquartered?
Syncromune is based in Fort Lauderdale, Florida, United States.
How many employees does Syncromune have?
Syncromune is in the 11-50 employee band.
How does Syncromune's funding compare to other Biotechnology startups?
Syncromune's latest round of $100M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Syncromune Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Syncromune is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.